Polygenic risk scores and the need for pharmacotherapy in neonatal abstinence syndrome.

ABSTRACT:

Background

The aim of this study was to identify genetic variants associated with NAS through a genome-wide association study (GWAS) and estimate a Polygenic Risk Score (PRS) model for NAS.

Methods

A prospective case-control study included 476 in utero opioid-exposed term neonates. A GWAS of 1000 genomes-imputed genotypes was performed to identify variants associated with need for pharmacotherapy for NAS. PRS models for estimating genetic predisposition were generated via a nested cross-validation approach using 382 neonates of European ancestry. PRS predictive ability, discrimination, and calibration were assessed.

Results

Cross-ancestry GWAS identified one intergenic locus on chromosome 7 downstream of SNX13 exhibiting genome-wide association with need for pharmacot

SUBMITTER: Bibi S 

PROVIDER: S-EPMC9931940 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature